Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crvs · stock forecast · 13 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$42.00
Consensus
$33.17
+195.9% upside
Low
$27.00
Median: $31 · Last Close: $11.21
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$33.17
195.9% upside
High Target
$42
274.7%
Low Target
$27
140.9%
Current Price
$11.21
as of today
Based on analyst price targets, the CRVS stock price prediction for the next 12 months ranges from $27 to $42. The consensus CRVS price forecast of $33.17 implies 195.9% upside from the current price of $11.21.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $10.65 | ↓ 5.00% |
1-day model range: $10.53–$10.77. Peak: $10.77 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRVS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-13 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-01-22 | Jefferies | Maintains | Buy→Buy |
| 2026-01-21 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-01-21 | Barclays | Maintains | Overweight→Overweight |
| 2026-01-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-20 | Mizuho | Maintains | Outperform→Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-03-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-26 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-01-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Corvus Pharmaceuticals, Inc. (CRVS) stock. Of the recent 41 rating actions, 1 were upgrades and 2 were downgrades. 13 analysts currently cover CRVS.
Analyst Recommendation Trends
CRVS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$-0M
↓ 100.6% YoY
Revenue Next Year
$5M
↓ 2372.8% YoY
EPS This Year
$-0.68
EPS Next Year
$-0.85
↑ 25.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRVS EPS of $-0.68 for the current fiscal year, based on estimates from 4 analysts. The CRVS revenue forecast is $-0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRVS stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRVS price target is $33.17 (+195.9% upside), with an analyst consensus of Buy.
The CRVS short-term stock prediction for tomorrow is $10.65 (-5.00%).
Corvus Pharmaceuticals, Inc. trades on NASDAQ under the ticker CRVS. The CRVS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 92% of covering analysts.
Frequently asked questions
CRVS forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month CRVS price target is $33.17, with a high forecast of $42.00 and a low of $27.00. The median price target is shown in the chart above when available. This implies +195.9% potential upside from the current price of $11.21.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.